BriaCell reports complete lung metastasis resolution in breast cancer study

PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a biotechnology firm focused on developing immunotherapies for cancer treatment, has reported a complete resolution of lung metastasis in a patient with metastatic breast cancer following treatment with its Bria-OTS therapy. According to InvestingPro data, the company, currently valued at $2.5M, is in development stage with revenue of $0.32M in the last twelve months. The company confirmed the outcome at a four-month follow-up after initially observing the response two months into the Phase 1/2a clinical trial.

The patient, a 78-year-old woman with hormone receptor-positive breast cancer, had not responded to several previous therapies. She was administered Bria-OTS, an off-the-shelf personalized immunotherapy, and after receiving intradermal injections every two weeks for six weeks, followed by dosing every three weeks, her lung metastasis was resolved, with stable disease observed in other areas. While the clinical results are promising, InvestingPro analysis indicates the company is quickly burning through cash, with an EBITDA of -$4.22M.

Neal S. Chawla MD, Principal Investigator for the Bria-OTS study, expressed optimism about the initial data, which showed rapid and robust anti-tumor activity in a hormone receptor-positive patient. Dr. William V. Williams, President and CEO of BriaCell, highlighted the significance of this result as an early validation of the company’s personalized immunotherapy approach.

The Bria-OTS platform is now under investigation in a Phase 1/2a dose-escalation study for metastatic recurrent breast cancer. The study aims to evaluate the safety and efficacy of Bria-OTS as monotherapy and in combination with an immune checkpoint inhibitor.

BriaCell’s announcement comes amid a landscape where patients with hormone receptor-positive disease have limited treatment options, despite recent advances with antibody-drug-conjugates and immune checkpoint inhibitors. The company’s findings could represent a step forward in providing new therapeutic avenues for individuals with metastatic breast cancer.

The ongoing clinical trial is registered on ClinicalTrials.gov with identifier NCT06471673. BriaCell continues to monitor the patient’s response and plans to replicate the study’s results in other patients with metastatic breast cancer and potentially other cancer types.

This report is based on a press release statement by BriaCell Therapeutics Corp. and has not been independently verified. For comprehensive financial analysis and additional insights about BriaCell’s performance, including 8 more exclusive ProTips, visit InvestingPro. The platform’s Financial Health Score currently rates the company as WEAK (1.24), reflecting its development-stage status and financial metrics.

In other recent news, BriaCell Therapeutics Corp. has reported encouraging results from its Phase 2 study of Bria-IMT in combination with checkpoint inhibitors for treating metastatic breast cancer. The study showed a median overall survival of 17.3 months for hormone receptor-positive patients, surpassing the 14.4 months associated with the current standard of care, TRODELVY®. Additionally, the regimen demonstrated comparable results for triple-negative breast cancer patients. In another development, BriaCell announced that its Phase 3 study of Bria-IMT will continue following a positive safety review by the Data Safety Monitoring Board. The study has received Fast Track Designation from the FDA, highlighting the urgency of developing new treatments for metastatic breast cancer. Furthermore, BriaCell has announced plans for a public offering of common shares, with ThinkEquity acting as the sole placement agent. The proceeds from this offering are intended for working capital and advancing the company’s business objectives. The offering will be contingent on market conditions, and potential investors are advised to review the relevant documents filed with the U.S. Securities and Exchange Commission.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.